

7/2/15

BOARD OF REGENTS OF THE UNIVERSITY OF WISCONSIN SYSTEM

I.2. Business and Finance Committee

Thursday, July 9, 2015  
8:45 a.m. – 9:00 a.m.  
1220 Linden Drive  
1820 Van Hise Hall  
Madison, Wisconsin

- a. Approval of the Minutes of the June 4, 2015 Meeting of the Business and Finance Committee
- b. UW-Madison Contractual Agreement – Novartis Pharmaceuticals Corporation  
[Resolution I.2.b.]
- c. UW-Madison Contractual Agreement – Genentech, Inc.  
[Resolution I.2.c.]
- d. UW-Madison Contractual Agreement – Madison Vaccines, Inc.  
[Resolution I.2.d.]

UW-Madison Contractual Agreement  
with Novartis Pharmaceuticals Corporation.

BUSINESS AND FINANCE COMMITTEE

Resolution:

That, upon the recommendation of the Chancellor of the University of Wisconsin-Madison and the President of the University of Wisconsin System, the Board of Regents approves the contractual agreement between the Board of Regents of the University of Wisconsin System, doing business as UW-Madison, and Novartis Pharmaceuticals Corporation.

July 9, 2015

Agenda Item I.2.b.

**UW-MADISON CONTRACTUAL AGREEMENT  
WITH NOVARTIS PHARMACEUTICALS CORPORATION**

**EXECUTIVE SUMMARY**

**BACKGROUND**

UW System Board of Regents policy requires any grant or contract with private profit-making organizations in excess of \$500,000 be presented to the Board for formal approval prior to execution.

**REQUESTED ACTION**

Adoption of Resolution I.2.b., approving the contractual agreement between the Board of Regents and Novartis Pharmaceuticals Corporation.

**DISCUSSION AND RECOMMENDATIONS**

The University of Wisconsin-Madison, with assistance from the Office of Research and Sponsored Programs at the University of Wisconsin-Madison, has negotiated a Sponsored Research Agreement with Novartis Pharmaceuticals Corporation. In consideration for providing the requested research, Novartis Pharmaceuticals Corporation shall pay the University \$665,468.99. The research project is anticipated to be conducted during the period from September 24, 2014 through September 2, 2018. The research will be conducted in the department of medicine, Comprehensive Cancer Center, under the direction of Kari Wisinski.

The study is titled, "A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo with tamoxifen and goserelin or a NSAID and goserelin for the treatment of premenopausal women with HR positive, HER2 negative advanced breast cancer." The research will be a Phase III Clinical Study.

**RELATED REGENT POLICIES**

Regent Policy Document 13-1, General Contract Signature Authority, Approval, and Reporting

UW-Madison Contractual Agreement  
with Genentech, Inc.

BUSINESS AND FINANCE COMMITTEE

Resolution:

That, upon the recommendation of the Chancellor of the University of Wisconsin-Madison and the President of the University of Wisconsin System, the Board of Regents approves the contractual agreement between the Board of Regents of the University of Wisconsin System, doing business as UW-Madison, and Genentech, Inc.

July 9, 2015

Agenda Item I.2.c.

## **UW-MADISON CONTRACTUAL AGREEMENT WITH GENENTECH, INC**

### **EXECUTIVE SUMMARY**

#### **BACKGROUND**

UW System Board of Regents policy requires any grant or contract with private profit-making organizations in excess of \$500,000 be presented to the Board for formal approval prior to execution.

#### **REQUESTED ACTION**

Adoption of Resolution I.2.c., approving the contractual agreement between the Board of Regents and Genentech, Inc.

#### **DISCUSSION AND RECOMMENDATIONS**

The University of Wisconsin-Madison, School of Medicine and Public Health, with assistance from the Office of Research and Sponsored Programs at the University of Wisconsin-Madison, has negotiated a Sponsored Research Agreement with Genentech, Inc. In consideration for providing the requested research, Genentech, Inc. shall pay the University \$692,125.92. The research project is anticipated to be conducted during the period from December 9, 2013 through March 1, 2016. The research will be conducted in the department of Pulmonary Medicine under the direction of Keith Meyer, M.D.

The study is titled, "A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study To Assess The Efficacy And Safety Of Lebrikizumab In Patients With Idiopathic Pulmonary Fibrosis." The research is a clinical trial of a drug.

#### **RELATED REGENT POLICIES**

Regent Policy Document 13-1, General Contract Signature Authority, Approval, and Reporting

UW-Madison Contractual Agreement  
with Madison Vaccines Incorporated

BUSINESS AND FINANCE COMMITTEE

Resolution:

That, upon the recommendation of the Chancellor of the University of Wisconsin-Madison and the President of the University of Wisconsin System, the Board of Regents approves the contractual agreement between the Board of Regents of the University of Wisconsin System, doing business as UW-Madison, and Madison Vaccines Incorporated.

**UW-MADISON CONTRACTUAL AGREEMENT  
WITH MADISON VACCINES INCORPORATED**

**EXECUTIVE SUMMARY**

**BACKGROUND**

UW System Board of Regents policy requires any grant or contract with private profit-making organizations in excess of \$500,000 be presented to the Board for formal approval prior to execution.

**REQUESTED ACTION**

Adoption of Resolution I.2.d., approving the contractual agreement between the Board of Regents and Madison Vaccines Incorporated.

**DISCUSSION AND RECOMMENDATIONS**

The University of Wisconsin-Madison, with assistance from the Office of Research and Sponsored Programs at the University of Wisconsin-Madison, has negotiated a Clinical Trial Agreement with Madison Vaccines Incorporated. In consideration for providing the requested research, Madison Vaccines Incorporated shall pay the University \$1,506,436.62. The study is anticipated to be conducted during the period from the date of signature through study completion (approximately 5.5 years). The research will be conducted in the Department of Medicine, Comprehensive Cancer Center, under the direction of Christos Kryiokopoulos.

The study is titled, "DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor." The research will be an investigator-initiated Phase I Study.

**RELATED REGENT POLICIES**

Regent Policy Document 13-1, General Contract Signature Authority, Approval, and Reporting